NOACs Beat Warfarin on Cognition and Outcomes in AF Plus Alzheimer's

This Swedish registry analysis addresses a near-complete evidence gap on anticoagulation choice in patients with coexisting atrial fibrillation and Alzheimer's disease, favoring non-vitamin K oral anticoagulants over warfarin and no anticoagulation across cognitive, thromboembolic, and safety endpoints.

NOACDOACwarfarinvitamin K antagonistatrial fibrillationAlzheimer's diseasedementiaanticoagulationcognitive declineischaemic strokemajor bleedingfractureobservational cohortSwedish registrySveDemstroke prevention Cardiology / Anticoagulation

Background Information

NOACs slow cognitive decline in AF with Alzheimer's disease.

Oral anticoagulants can impact both cognitive outcomes and overall clinical profiles in patients with atrial fibrillation (AF) and Alzheimer's disease (AD). Non-vitamin K oral anticoagulants (NOACs) resulted in slower cognitive decline and reduced risks of mortality, ischemic stroke, and fractures compared to non-use or warfarin. This study suggests NOACs may offer better outcomes than warfarin in AF patients with AD, with a comparable safety profile. NOACs may improve cognitive and clinical outcomes in patients with both AF and AD.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Zhu N, Xu H, Garcia-Ptacek S, Mitra S, Eriksdotter M

Citation: Zhu N, Xu H, Garcia-Ptacek S, et al. Oral anticoagulants, cognition, and clinical outcomes in atrial fibrillation and Alzheimer's disease: a Swedish nationwide study. European heart journal. 2026. doi:10.1093/eurheartj/ehag584

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →